This website is intended for healthcare professionals only

Trending Topic

16 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]

Clara Chow, ESC 2021 – the QUARTET Study

8 mins 10
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Sep 24th 2021

Dr Clara Chow (Professor of Medicine, Academic Director Westmead Applied Research Centre, University of Sydney, Sydney, Australia) kindly shared her thoughts on the limitations of current treatment paradigms for hypertension, the quad pill for hypertension, and the QUARTET study, from the virtual ESC Congress 2021.

Questions

  1. What are the limitations of current treatment paradigms for hypertension? (0.18)
  2. What is the composition of the quad pill for hypertension, and what is the rationale for its use? (1.26)
  3. What have clinical studies to date taught us about the efficacy and safety of this approach? (2.38)
  4. What were the aims, design and eligibility criteria of the QUARTET study? (3.41)
  5. What are the strengths and limitations of this study? (6.01)

Speaker disclosures: Dr Clara Chow has nothing to declare in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.

Filmed during a remote video call with Dr Clara Chow as a highlight of ESC 2021, August 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup